Recently, the optimism surrounding blockbuster weight-loss drugs has propelled a few mega-cap health care stocks to dizzying valuations. But the opportunities for profitable growth in the Health Care sector go far beyond headline-makers and market darlings. Join Harding Loevner Health Care analyst David Glickman as he shares his framework for identifying high quality companies with prospects for sustainable growth in health care. From the promise of mRNA technology in oncology to biologic drug contract manufacturing dynamics, AI in health care, and next generation innovations still flying under the radar, David will explore some of the newer advancements shaping the future of health care. He’ll also discuss the critical role of quality, a cornerstone of Harding Loevner’s investment approach, in choosing investments and the challenge of maintaining a long-term investment horizon in a sector defined by constant change.
To view David Glickman's bio - click here!
Thursday, March 6th11:45 am - 1:00 pm
Springhill Suites4601 Frey StMadison, WI 53705
Register Now!
ADMIN